Related Experiment Videos
Adjuvant chemotherapy for patients with stage II nonseminomatous testis cancer
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Seminars in Oncology
|December 1, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Bone metastasis in cancer: from microenvironmental remodeling to precision therapy.
Seminars in oncology·2026
Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study.
Seminars in oncology·2026
NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.
Seminars in oncology·2026
Dual alexithymia: A relational framework for clinical communication in oncology.
Seminars in oncology·2026
SPIB as a context-specific regulator in cancer: from molecular mechanisms to clinical implications.
Seminars in oncology·2026